ReviewFrontiers in microbiology2025
Gut microbiota dysbiosis in polycystic ovary syndrome: focus on diet, probiotics, and traditional Chinese medicine.
Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Exploring emerging concepts in the pathophysiology of PCOS: microbiome dysbiosis and immunological dysregulation.Reproduction & fertility · 2026Review
- Cardiometabolic Health During the Climacteric Transition: A Narrative Review of Lifestyle, Physiological, and Nutritional Approaches.Healthcare (Basel, Switzerland) · 2026Review
- Algae-Derived Bioactives Reprogram the Gut-SIRT1-Kisspeptin Axis in Polycystic Ovary Syndrome.Marine drugs · 2026Review
- The Role of Antioxidants in the Management of Polycystic Ovary Syndrome.Antioxidants (Basel, Switzerland) · 2026Review
- Orchestrating the gut microbiota-mitochondrial-immune axis in gynecological diseases: mechanisms and dual-targeting therapeutic strategies.Frontiers in reproductive health · 2026Review
- Decoding the gut-adipose-ovary axis in polycystic ovary syndrome: from metabolic dysregulation to oncological risk modulation.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, primarily characterized by symptoms such as ovulatory dysfunction, hyperandrogenism, and polycystic ovarian morphology. In recent years, research has revealed that gut microbiota dysbiosis plays a crucial role in the pathogenesis of PCOS. Diet, as an essential factor in regulating gut microbiota, significantly impacts the clinical presentation and metabolic status of PCOS patients. Although substantial research has explored the relationship between PCOS and gut microbiota, many controversies and gaps remain, including the unclear mechanisms by which dietary structure and nutritional interventions specifically influence PCOS. This review aims to summarize the interaction between PCOS and gut microbiota, explore the role of diet in modulating gut microbiota and improving the pathological state of PCOS, and evaluate the potential therapeutic effects of probiotics, high-fat diets, and ketogenic diets on PCOS. Ultimately, it looks forward to personalized nutritional treatment strategies based on gut microbiota and future research directions, providing new insights into the treatment of PCOS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.